Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis

Trial Profile

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms RESI
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2016 Patients are receiving Rebif/Avonex now. Thus changes in purpose, primary end points and treatment.
    • 02 Jun 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top